The Role of Atrial Natriuretic Peptide in the Lipolytic Process: Effect of Obesity and Exercise (BALO)

The Contribution of Atrial Natriuretic Peptide in Lipid Mobilization of Subjects With Obesity, Both During Rest and Exercise

In the developing countries, obesity prevalence is on a dramatic rise. Obesity is related to co-morbidities and as a result, obesity significantly shortens life expectancy and lowers quality of life. To prevent this, participation in exercise or training programs is absolutely necessary, in order to generate adipose tissue mass loss. The amount of adipose tissue mass loss is, amongst others, dependent on lipolysis which is under endocrine regulation by, mainly, catecholamines, insulin and atrial natriuretic peptide. However, large variations in adipose tissue mass loss and gain are likely in obese subjects, possibly due to a decreased lipolytic effect of these hormones (as was shown for catecholamines in the subcutaneous adipose tissue of obese subjects). However, the relative contribution of atrial natriuretic peptide in the lipolytic process remains elusive, particularly in subjects with obesity, which show an increased plasma expression of atrial natriuretic peptide.

The aim of the present study is to observe the contribution of atrial natriuretic peptide in the subcutaneous adipose tissue of obese subjects. This will be tested by measurements of extracellular glycerol levels (by microdialysis) in the subcutaneous adipose tissue in situ at rest and during endurance exercise under local beta- and alpha-blockade.

Eventually, the knowledge gained from this research will contribute to the optimization of exercise programs for people with obesity.

Study Overview

• Status: Completed
• Conditions: Obesity
• Intervention / Treatment: Other: subcutaneous adipose tissue microdialysis under local beta/alpha blockade

• Study Type: Observational
• Enrollment (Actual): 30

Contacts and Locations

Study Locations

• Belgium
  • Diepenbeek, Belgium, 3590
    • Hasselt University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

• Sampling Method: Non-Probability Sample

Study Population

subjects with obesity

Description

Inclusion Criteria:

• Obese group: BMI > 30 kg/m², sedentary (no regular physical activity last 6 months), insulin sensitive or insulin resistant
• Lean controls: BMI > 18.5 kg/m² and < 25 kg/m², regular physical activity, insulin sensitive

Exclusion Criteria:

• Regular glucose lowering medication or beta blockade medication
• Presence of chronical diseases
• Orthopedic or neurological problems

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
persons with obesity	Other: subcutaneous adipose tissue microdialysis under local beta/alpha blockade; adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
lean persons	Other: subcutaneous adipose tissue microdialysis under local beta/alpha blockade; adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Subcutaneous adipose tissue microdialysis	abdominal subcutaneous adipose tissue microdialysis during rest and exercise; basal + under local alpha- and beta-blockade.	week 1
Atrial natriuretic peptide (ANP) Response	measurement systemic ANP response (venous blood sampling)	week 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Central insulin sensitivity	Fasting serum insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity derived from an oral glucose tolerance test (75g)	screening
Echocardiography	heart function by means of standard echocardiography	Day 1
Maximal oxygen uptake (ml/O2/kg/min)	measured using indirect calorimetry and an incremental bicycle protocol	Day 1
Anthropometry	body composition, measured using dual x-ray absorptiometry, height, weight, waist and hip circumference	screening
Abdominal subcutaneous adipose tissue biopsy	biochemical, proteomics and morphological analyses	week 1

Collaborators and Investigators

• Sponsor: Hasselt University
• Collaborators: Jessa Hospital; Maastricht University
• Investigators: Principal Investigator: Ellen Blaak, prof. dr., Maastricht University; Study Chair: Kenneth Verboven, drs, Hasselt University

Study record dates

Study Major Dates

• Study Start: August 1, 2014
• Primary Completion (Actual): August 1, 2016
• Study Completion (Actual): November 1, 2016

Study Registration Dates

• First Submitted: March 17, 2015
• First Submitted That Met QC Criteria: April 13, 2015
• First Posted (Estimate): April 16, 2015

Study Record Updates

• Last Update Posted (Estimate): November 18, 2016
• Last Update Submitted That Met QC Criteria: November 17, 2016
• Last Verified: November 1, 2016

More Information

Terms related to this study

• Keywords: obesity; microdialysis; lipolysis; adipose tissue lipolysis; atrial natriuretic peptide
• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Overweight; Body Weight; Obesity
• Other Study ID Numbers: CME2014 /450

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED